John Allen, MD
Ophthalmology · Charlotte, NCNPI 1689968216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Astellas Pharma US Inc at 28.6% of the total. 2025 is the largest year on record at $1,310, 7.5 times the $174 reported in 2019.
Across 73 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$693
- Apellis Pharmaceuticals, Inc.$487
- Regeneron Healthcare Solutions, Inc.$393
- AbbVie$218
- Amgen$125
- Genentech USA, Inc.$104
- plus $401 from 9 others
Across 6 payments — averaging $19,849 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$119K
What the payments were for
- Food & beverage$2,421100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $693 |
| Apellis Pharmaceuticals, Inc. | 9 | $487 |
| Regeneron Healthcare Solutions, Inc. | 16 | $393 |
| AbbVie(2 entities) | 12 | $218 |
| Amgen | 1 | $125 |
| Genentech USA, Inc. | 5 | $104 |
| Alimera Sciences, Inc. | 6 | $100 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 2 | $67 |
| Davol Inc. | 1 | $34 |
| Novartis | 2 | $33 |
| Oculus Surgical Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Eyepoint US, Inc. | 1 | $21 |
| Optinose US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,421 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 128 | $4,420 |
| Ketorolac Tromethamine | 99 | $2,429 |
| Brimonidine Tartrate | 13 | $789 |
| Dorzolamide Hcl | 13 | $401 |
| Timolol Maleate | 25 | $329 |
| Ciprofloxacin Hcl | 13 | $157 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Charlotte
- Thomas MundorfCharlotte$220K
- Charles BlotnickCharlotte$18K
- Adrian ElfersyCharlotte$13K
- Joseph KrugCharlotte$10K
- Royce SyracuseCharlotte$10K
- William HammondsCharlotte$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.